Lifecore Biomedical, Inc. (LFCR)
LFCR Stock Price Chart
Explore Lifecore Biomedical, Inc. interactive price chart. Choose custom timeframes to analyze LFCR price movements and trends.
LFCR Company Profile
Discover essential business fundamentals and corporate details for Lifecore Biomedical, Inc. (LFCR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
15 Feb 1996
Employees
524.00
Website
https://www.lifecore.comCEO
Paul Josephs
Description
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.
LFCR Financial Timeline
Browse a chronological timeline of Lifecore Biomedical, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 1 Apr 2026
Upcoming earnings on 31 Dec 2025
Upcoming earnings on 3 Oct 2025
EPS estimate is -$0.30, while revenue estimate is $26.68M.
Earnings released on 7 Aug 2025
EPS came in at -$0.10 falling short of the estimated -$0.09 by -11.11%, while revenue for the quarter reached $36.44M , beating expectations by +44.33%.
Earnings released on 3 Apr 2025
EPS came in at -$0.19 falling short of the estimated -$0.14 by -35.71%, while revenue for the quarter reached $35.15M , missing expectations by -0.59%.
Earnings released on 2 Jan 2025
EPS came in at -$0.25 surpassing the estimated -$0.27 by +7.41%, while revenue for the quarter reached $32.56M , missing expectations by -2.00%.
Earnings released on 26 Aug 2024
EPS came in at -$0.15 falling short of the estimated -$0.12 by -25.00%, while revenue for the quarter reached $24.71M , missing expectations by -16.95%.
Earnings released on 9 Aug 2024
EPS came in at -$0.41 falling short of the estimated -$0.12 by -241.67%, while revenue for the quarter reached $37.89M , beating expectations by +27.35%.
Earnings released on 22 May 2024
EPS came in at $0.43 surpassing the estimated -$0.23 by +285.65%, while revenue for the quarter reached $35.70M , beating expectations by +46.21%.
Earnings released on 29 Dec 2023
EPS came in at $0.39 surpassing the estimated -$0.23 by +269.74%, while revenue for the quarter reached $30.15M , beating expectations by +22.86%.
Earnings released on 31 Aug 2023
EPS came in at -$0.89 falling short of the estimated -$0.07 by -1.17K%, while revenue for the quarter reached $24.52M , missing expectations by -0.07%.
Earnings released on 1 Jun 2023
EPS came in at -$0.22 falling short of the estimated -$0.13 by -69.23%, while revenue for the quarter reached $31.55M , beating expectations by +8.70%.
Earnings released on 16 May 2023
EPS came in at -$0.22 falling short of the estimated -$0.13 by -69.23%, while revenue for the quarter reached $26.54M , missing expectations by -5.23%.
Earnings released on 16 Mar 2023
EPS came in at -$0.24 falling short of the estimated -$0.04 by -500.00%, while revenue for the quarter reached $21.86M , missing expectations by -53.09%.
Earnings released on 6 Oct 2022
EPS came in at -$0.32 falling short of the estimated -$0.13 by -146.15%, while revenue for the quarter reached $43.36M , beating expectations by +1.44%.
Earnings released on 10 Aug 2022
EPS came in at -$0.01 falling short of the estimated -$0.01 by -25.00%, while revenue for the quarter reached $47.63M , beating expectations by +3.86%.
Earnings released on 5 Apr 2022
EPS came in at -$0.08 falling short of the estimated -$0.01 by -1.50K%, while revenue for the quarter reached $53.07M , beating expectations by +9.63%.
Earnings released on 5 Jan 2022
EPS came in at $0.05 surpassing the estimated $0.02 by +225.10%, while revenue for the quarter reached $129.49M , missing expectations by -1.66%.
Earnings released on 29 Sept 2021
EPS came in at -$0.23 falling short of the estimated -$0.12 by -91.67%, while revenue for the quarter reached $128.79M .
Earnings released on 28 Jul 2021
EPS came in at $0.07 surpassing the estimated $0.01 by +975.27%, while revenue for the quarter reached $139.83M .
Earnings released on 7 Apr 2021
EPS came in at -$0.09 falling short of the estimated -$0.02 by -475.08%, while revenue for the quarter reached $137.78M .
Earnings released on 6 Jan 2021
EPS came in at $0.02 surpassing the estimated $0.01 by +100.00%, while revenue for the quarter reached $130.90M .
Earnings released on 6 Oct 2020
EPS came in at -$0.11 matching the estimated -$0.11, while revenue for the quarter reached $135.64M .
LFCR Stock Performance
Access detailed LFCR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.